Adaptive Image-Guided Radiotherapy (IGRT) for lung cancer using repeat treatment planning CT scan and PET-CT scans.

Adaptive Image-Guided Radiotherapy (IGRT) for lung cancer using repeat treatment planning CT scan and PET-CT scans. - Repeat imaging for treatment planning during radiotherapy in lung cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON30265

Enrollment

Registered

2006-12-08

Start date

2006-12-01

Completion date

Unknown

Last updated

2024-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cancer of the airways lung cancer

Interventions

The treating clinician will decide if the plan will have to be modified in accordance with the following criteria. Geometric displacement will always be corrected. Reductions in field sizes for prim

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Eligible patients who will undergo a 4DCT or 4DCT-PET planning scan, and in whom (i) a pre-treatment GTV can be identified and (ii) will receive a minimum dose of 46 Gy in 4 weeks

Exclusion criteria

Exclusion criteria: Patients who will be irradiated after a complete response to chemotherapy or after a complete surgical resection

Design outcomes

Primary

Measure	Time frame
1.To establish the proportion of patients in whom an initial radiotherapy plan does not provide similar or improved coverage on a repeat planning procedure after 15 fractions. 2. To indentify the characteristics of this sub-population of patients and design adaptiveimaging protocols to account for time trends. 3. Establish the magnitude of reduction in toxicity risk to lung and esophagus in patients for whom reductions in PTV are possible	—

Measure

Time frame

1.To establish the proportion of patients in whom an initial radiotherapy plan does not provide similar or improved coverage on a repeat planning procedure after 15 fractions. 2. To indentify the characteristics of this sub-population of patients and design adaptiveimaging protocols to account for time trends. 3. Establish the magnitude of reduction in toxicity risk to lung and esophagus in patients for whom reductions in PTV are possible

—

Secondary

Measure	Time frame
nvt	—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)